生物合成的银纳米粒子及其抗糖尿病潜力
Angélica Sofía González-Garibay1, Omar Ricardo Torres-González1, Iván Moisés Sánchez-Hernández1
1Medical and Pharmaceutical Biotechnology Unit, Center for Research and Assistance in Technology and Design of the State of Jalisco, A.C. (CIATEJ). Av. Normalistas No. 800 Col. Colinas de la Normal, Guadalajara C.P. 44270, Jalisco, Mexico.
Pharmaceuticals (Basel, Switzerland)
|September 27, 2025
概括
生物合成的银纳米粒子 (AgNPs) 通过影响关键代谢途径,显示出对治疗糖尿病的巨大潜力. 目前正在进行的研究强调了它们作为一种新的治疗方法来调节血糖的承诺.
科学领域:
- 纳米技术和材料科学 材料科学
- 生物化学和分子生物学
- 药理学和治疗学 药理学和治疗学
背景情况:
- 糖尿病是一种代谢障碍,具有持续的管理挑战.
- 生物合成的银纳米粒子 (AgNPs) 正在成为一种新的治疗途径.
- AgNPs对与葡萄糖平衡相关的酶和信号通路产生潜在影响.
研究的目的:
- 审查生物合成AgNP的抗糖尿病活性目前的研究.
- 分析在体外和体内评估AgNPs用于糖尿病管理的研究.
- 介绍最近的研究成果和对糖尿病治疗中AgNP的未来前景.
主要方法:
- 通过PubMed搜索使用"抗糖尿病 + 活性 + AgNPs"识别的研究的叙述性综述.
- 专注于来自植物来源的生物合成的AgNP.
- 对实验方法,植物来源,纳米粒子特性,度和结果的分析.
主要成果:
- 使用植物生物活性化合物的AgNP的绿色合成是一种环保的方法.
- 植物提取物是AgNP生物合成的主要生物材料.
- 在体外研究中经常评估α-葡萄糖酶/α-氨酶抑制;在体内研究中关注血糖水平.
结论:
- 越来越多的科学证据支持AgNPs的抗糖尿病潜力.
- AgNPs为新的糖尿病管理策略提供了一个有希望的领域.
- 需要进一步的研究来充分阐明和利用AgNPs的治疗益处.
相关概念视频
Oral Hypoglycemic Agents: Biguanides and Glitazones
585
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
585
Insulin: Biosynthesis, Chemistry, and Preparation
1.2K
The endoplasmic reticulum (ER) of pancreatic β-cells synthesizes preproinsulin, which consists of a signal peptide, A and B chains, and a C-peptide. Preproinsulin is then cleaved and folded into proinsulin, which translocates to the Golgi apparatus for sorting and packaging into secretory granules. In these granules, enzymatic clipping generates insulin and C-peptide.
Damage or functional impairment of β-cells inhibits insulin production, leading to diabetes. Diabetes treatment...
Damage or functional impairment of β-cells inhibits insulin production, leading to diabetes. Diabetes treatment...
1.2K
Oral Hypoglycemic Agents: Glinides
600
Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively...
600
Oral Hypoglycemic Agents: Sulfonylureas
781
Sulfonylureas are oral hypoglycemic agents utilized in treating type 2 diabetes. They are characterized by their unique sulfonylurea chemical structure. The family of sulfonylureas is divided into generations. First-generation sulfonylureas, including tolbutamide (Orinase), chlorpropamide (Diabinese), and tolazamide (Tolinase), trigger insulin release from pancreatic β cells and enhance peripheral tissues' insulin sensitivity. The second-generation members, such as glipizide...
781


